Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc.（QLGN）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · QLGN · 截至 2026年6月9日
活动摘要
买入笔数
4
P-Purchase only
卖出笔数
0
近12个月
买卖比
∞
Buy/Sell (by trades)
整体情绪
Qualigen Therapeutics, Inc.内部人在过去近12个月净买入股份，可能反映对公司前景的信心。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
QLGN 季度内部人买卖趋势
QLGN 内幕交易卖出 · QLGN 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
近期内幕交易记录
QLGN 高管卖出股份 · QLGN 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 22, 2022 | Poirier Michael S. Chairman and CEO | Purchase | 30,000 | $17K | Form 4 |
| Jun 14, 2022 | BROIDRICK AMY S. President/CSO | Purchase | 30,000 | $19K | Form 4 |
| Aug 19, 2021 | Kruger Kurt H Director | Purchase | 4,000 | $5K | Form 4 |
| Aug 19, 2021 | Kruger Kurt H Director | Purchase | 4,000 | $5K | Form 4 |
| Apr 26, 2021 | BROIDRICK AMY S. EVP, Chief Strategy Officer · Director | Purchase | 4,500 | $9K | Form 4 |
| Apr 20, 2021 | Poirier Michael S. Chairman, CEO & President · Director | Purchase | 11,005 | $20K | Form 4 |
| Apr 16, 2021 | Lotz Christopher L. Vice President of Finance, CFO | Purchase | 2,700 | $5K | Form 4 |
| Dec 29, 2020 | Kruger Kurt H Director | Purchase | 4,000 | $12K | Form 4 |
| Nov 23, 2020 | Kruger Kurt H Director | Purchase | 4,600 | $16K | Form 4 |
| Nov 20, 2020 | Kruger Kurt H Director | Purchase | 1,400 | $5K | Form 4 |
| May 22, 2020 | Poirier Michael S. Chairman, President & CEO. · Director | Other | 169,192 | — | Form 4 |
| May 22, 2020 | Lotz Christopher L. VP of Finance, CFO. | Other | 9,841 | — | Form 4 |
| Apr 10, 2020 | FOEHR MATTHEW W Director | Award | 38,461 | — | Form 4 |
| Jan 21, 2020 | FOEHR MATTHEW W Director | Other | 76,923 | — | Form 4 |
| Mar 12, 2020 | Doyle Noah Director | Sale | 500,000 | $110K | Form 4 |
| Mar 4, 2020 | Ritter Ira E. COB, CSO · Director | Sale | 18,750 | $7K | Form 4 |
| Mar 4, 2020 | Ritter Andrew J CEO and President · Director | Sale | 18,750 | $7K | Form 4 |
| Feb 25, 2020 | Doyle Noah Director | Option | 500,000 | $75K | Form 4 |
BROIDRICK AMY S.
EVP, Chief Strategy Officer · Director
日期
Apr 26
股数
4,500
均价
$2.03
总金额
$9K
Poirier Michael S.
Chairman, CEO & President · Director
日期
Apr 20
股数
11,005
均价
$1.80
总金额
$20K
Lotz Christopher L.
Vice President of Finance, CFO
日期
Apr 16
股数
2,700
均价
$1.86
总金额
$5K
Poirier Michael S.
Chairman, President & CEO. · Director
日期
May 22
股数
169,192
均价
—
总金额
—
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 QLGN 内幕交易
QLGN 内幕交易
Qualigen Therapeutics, Inc.（QLGN）内幕交易数据来源于公司内部人（包括QLGN）提交的SEC Form 4申报文件。过去12个月内，0位内部人向SEC提交了交易申报。QLGN内部人近期主要在买入，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Qualigen Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
QLGN 内幕交易 · 5个问题Qualigen Therapeutics, Inc.（QLGN）的内部人包括高管和董事，如QLGN等。过去12个月内，0位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026